57 results
DEF 14A
MREO
Mereo Biopharma Group Plc
24 Apr 24
Definitive proxy
7:30am
BENDER TO THE BOARD OF DIRECTORS
PROPOSAL 7 — RE-ELECTION OF ANDERS EKBLOM TO THE BOARD OF DIRECTORS
BOARD OF DIRECTORS AND CORPORATE GOVERNANCE
DIRECTORS … . Jeremy Bender and Dr. Anders Ekblom with the support of the Nomination and Corporate Governance Committee, the Board is satisfied that their performance
10-K
2023 FY
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
additional time to new compliance initiatives and corporate governance matters.
Failure to establish and maintain effective internal controls could … and corporate governance matters.
We determined at the end of our second fiscal quarter that, as of January 1, 2024, we no longer qualified as a “foreign
10-K
2023 FY
EX-10.30
MREO
Mereo Biopharma Group Plc
27 Mar 24
Annual report
5:20pm
entities, whether through ownership of voting securities, by contract relating to voting rights or governance, or otherwise. For clarity, once a Person
6-K
MREO
Mereo Biopharma Group Plc
16 Nov 23
Current report (foreign)
7:01am
. As a foreign private issuer, the Company follows certain home country corporate governance practices rather than the corporate governance requirements … to, requirements with respect to the composition of the Company’s board of directors and committees, certain corporate governance matters and shareholder
6-K
EX-99.1
MREO
Mereo Biopharma Group Plc
16 Nov 23
Current report (foreign)
7:01am
as a “foreign private issuer” under the Exchange Act. As a “foreign private issuer”, the Company relies on certain home country governance practices rather … than the corporate governance requirements of Nasdaq applicable to U.S. domestic companies, as is permitted by the listing requirements of Nasdaq
6-K
whyi83t1 lij35xx
5 May 23
Mereo BioPharma Announces Listing Transfer to Nasdaq Capital Market
5:06pm
6-K
5s9ao
10 Nov 22
Current report (foreign)
4:06pm
6-K
EX-99.2
4uhi92ay38
28 Oct 22
Mereo BioPharma Reaches Cooperation Agreement with Rubric Capital Management
7:11am
6-K
EX-99.1
oat6ir8ch tchu3h
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.2
kpqpx 0osbw
21 Oct 22
Mereo BioPharma Files Shareholder Circular for Upcoming General Meeting
7:06am
6-K
EX-99.1
zhcqjncadtne9z11
31 Aug 22
Letter Reiterates Mereo’s Updated Strategic Plan to Maximize Value for All Shareholders and Corrects Rubric’s Assumptions
7:57am
6-K
EX-99.1
smm ubh5v0fwl
22 Aug 22
Notifies Rubric of Certain Deficiencies in its Notice Purporting to Call a General Meeting of Shareholders
4:06pm
6-K
vcxpdq474z ly
26 May 22
Current report (foreign)
4:11pm
6-K
ixd375loaqvws6k7
26 Oct 21
Current report (foreign)
4:16pm
F-3/A
kvu vl0ud5oedaoi93
27 Sep 21
Shelf registration (foreign) (amended)
4:18pm
F-3/A
jqxopynyhns jb5
7 Sep 21
Shelf registration (foreign) (amended)
4:06pm